surmount-1 trial tirzepatide obesity without diabetes SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight

21.35

★★★★☆4.8 (126)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky

21.41

★★★★★4.9 (98)

In the SURMOUNT-1 trial (published in NEJM in July 2022) in participants with #obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.

24.09

★★★★★5.0 (157)

Tirzepatide lowers body weight for adults with obesity, regardless of disease duration

28.50

★★★★★4.7 (84)

SURMOUNT-1 Trial

23.48

★★★★★4.9 (203)

SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes

20.48

★★★★★5.0 (176)

💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers

28.50

★★★★★4.8 (132)